Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 18/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.38 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.36 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 2/20 | 0.34 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4860133 | 0.92 | TGFBR1 (0.44) | TGFBR1MAPK14TGFBR2MAP3K20 | |
| SCHEMBL4857773 | 0.86 | TGFBR1 (0.53) | TGFBR1MAPK14MTOR | |
| SCHEMBL4866825 | 0.85 | TGFBR1 (0.35) | TGFBR1MAPK14TGFBR2MAP3K20GRM5 | |
| SCHEMBL4866974 | 0.83 | TGFBR1 (0.38) | TGFBR1MAPK14TGFBR2MAP3K20 | |
| SCHEMBL4866956 | 0.83 | TGFBR1 (0.38) | TGFBR1MAPK14TGFBR2MAP3K20 | |
| SCHEMBL4867398 | 0.82 | TGFBR1 (0.50) | TGFBR1MAPK14 | |
| SCHEMBL4867631 | 0.81 | PIK3CD (0.40) | TGFBR1MAPK14MTOR | |
| SCHEMBL4857758 | 0.77 | TGFBR1 (0.56) | TGFBR1MAPK14MTOR | |
| SCHEMBL4033452 | 0.77 | TGFBR1 (0.45) | TGFBR1MAPK14TGFBR2MAP3K20MTOR | |
| SCHEMBL4866821 | 0.76 | TGFBR1 (0.40) | TGFBR1MAPK14TGFBR2MAP3K20GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275235-A1 | NOVEL FUSED HETEROAROMATIC COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS | PFIZER INC. (US) | 2008-11-06 | — | — | US | claimed |
| EP-1601676-A2 | FUSED IMIDAZOLES AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS | Pfizer Products Inc. (US) | 2005-12-07 | — | — | EP | claimed |
| WO-2004078110-A2 | FUSED IMIZADOLES AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS | PFIZER PRODUCTS INC. (US) | 2004-09-16 | — | — | WO | claimed |
| US-20080275235-A1 | NOVEL FUSED HETEROAROMATIC COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS | PFIZER INC. (US) | 2008-11-06 | — | — | US | disclosed |
| US-7417041-B2 | Imidazopyrimidines as transforming growth factor (TGF) inhibitors | PFIZER INC. (US) | 2008-08-26 | — | — | US | disclosed |
| EP-1601676-A2 | FUSED IMIDAZOLES AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS | Pfizer Products Inc. (US) | 2005-12-07 | — | — | EP | disclosed |
| WO-2004078110-A2 | FUSED IMIZADOLES AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS | PFIZER PRODUCTS INC. (US) | 2004-09-16 | — | — | WO | disclosed |
| US-20040176390-A1 | Novel fused heteroaromatic compounds as transforming growth factor (TGF) inhibitors | PFIZER INC | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275235-A1 | NOVEL FUSED HETEROAROMATIC COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS | TGFBR1, SMAD3, SMAD2 | TGFBR1 1/4885MAPK14 1127/4885TGFBR2 4/4885 |
| US-20040176390-A1 | Novel fused heteroaromatic compounds as transforming growth factor (TGF) inhibitors | SMAD3, TGFBR1, SMAD2 | TGFBR1 2/4885MAPK14 1223/4885TGFBR2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.